What Mosanna Therapeutics does

Mosanna Therapeutics is a clinical-stage, privately held biotechnology company founded in 2022 to develop a pharmaceutical treatment for Obstructive Sleep Apnea (OSA). The company is headquartered in Redwood City, California with a corporate entity in Basel, Switzerland, and operates with a lean team of 1–10 employees. Its single lead asset, MOS118, is a small molecule pan-K+ channel inhibitor formulated as a proprietary microparticle suspension and delivered via a nighttime nasal spray. The therapeutic mechanism is mechanistically distinct from existing OSA therapies: rather than mechanically splinting the airway (as CPAP does), MOS118 is designed to reactivate the body's natural Negative Pressure Reflex by stimulating pressure-sensing nerves in the nasopharynx, thereby increasing upper airway dilator muscle tone and reducing apnea and hypopnea episodes during sleep.

The target patient population is large and significantly underserved by current standards of care. OSA affects an estimated 80M+ people in the United States and 900M+ worldwide, and is associated with hypertension, cardiovascular disease, stroke, and elevated mortality. Existing first-line therapy (CPAP) is mechanical, frequently poorly tolerated, and adherence is low, leaving a sizeable unmet need for a non-invasive, pharmacology-based alternative that integrates into a bedtime routine. MOS118 is currently in Phase 2 clinical development following an $80 million Series A closed in June 2025 that was co-led by Pivotal bioVenture Partners and EQT Life Sciences.

The business model is pharmaceutical product sales through standard pharmacy and healthcare distribution channels once MOS118 receives regulatory approval. The company is pre-revenue and does not yet have commercial pricing or distribution infrastructure in place; capital raised to date funds clinical development, manufacturing, and regulatory activities. The investor syndicate combines specialized life sciences VCs (Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, Norwest) with returning seed investors (Forty51 Ventures, Supermoon Capital, High-Tech Gründerfonds). The leadership team is unusually experienced for a Phase 2 biotech: CEO David Weber, PhD previously led Otonomy through an IPO and Oculex to an Allergan acquisition; Chairman Ben Machielse has overseen multiple drug approvals; and Consulting CMO David White, MD (Harvard Medical School) is a leading authority in sleep-disordered breathing.

Name

Mosanna Therapeutics

Legal name

Mosanna Therapeutics, Inc.

Website

https://mosanna.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a nighttime nasal spray delivering a pan-K+ channel inhibitor that reactivates the body's natural airway reflex to treat obstructive sleep apnea patients.

Ownership category

akta.pro rank

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Mosanna Therapeutics is developing MOS118, a nasal spray therapeutic for obstructive sleep apnea. Once approved through clinical trials and regulatory review, the company will generate revenue through sales of its pharmaceutical product, likely distributed via pharmacy and healthcare channels.

Core offering

Mosanna Therapeutics is developing MOS118, a small molecule pan-K+ channel inhibitor formulated as a unique microparticle suspension for nasal administration at bedtime to treat Obstructive Sleep Apnea (OSA). The therapy works by stimulating pressure-sensing nerves in the nasopharynx to reactivate the body's natural Negative Pressure Reflex, increasing upper airway muscle tone and reducing apnea and hypopnea episodes during sleep. MOS118 is currently advancing through Phase 2 clinical trials as a pharmaceutical alternative to mechanical CPAP therapy.

Product overview

Mosanna Therapeutics is developing a single pharmaceutical product, MOS118, a nighttime nasal spray for the treatment of obstructive sleep apnea. The therapy is a small molecule pan-K+ channel inhibitor delivered as a nasal spray before bedtime, designed to reactivate the body's natural airway reflex by stimulating upper airway muscles to maintain an open airway during sleep.

Differentiator

Problem solved

Functional benefit

Products and services

• MOS118 A nasal spray therapeutic for obstructive sleep apnea (OSA) that delivers a small molecule pan-K+ channel inhibitor formulated as a microparticle suspension. The medication stimulates upper airway dilator muscles by activating pressure-sensing nerves in the nasopharynx, increasing airway muscle tone and reducing apnea and hypopnea episodes throughout the night.

Quantifiable outcome

• Reduces apnea and hypopnea episodes
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Apnimed: Apnimed is developing AD109, a once-nightly oral pharmaceutical combination targeting the upper airway for obstructive sleep apnea — the most directly comparable OSA pharmacotherapy peer to Mosanna's MOS118 nasal spray, competing for the same patient population and prescriber base.
• Inspire Medical Systems: Inspire Medical Systems markets an implantable neurostimulation device for moderate-to-severe OSA patients who fail CPAP. It represents an alternative non-CPAP therapy pathway competing for the same refractory OSA patient segment MOS118 targets.
• Nyxoah: Nyxoah is developing a battery-free neurostimulation implant for OSA as an alternative to CPAP and to Inspire's system. It competes in the same non-CPAP therapy category and addresses the same patient willingness-to-pay for non-mechanical alternatives.
• ProSomnus Sleep Technologies: ProSomnus manufactures precision oral appliance therapy devices for OSA as an alternative to CPAP. It targets the same CPAP-intolerant patient population Mosanna seeks to address with MOS118, representing a device-based competitive alternative.

Broad incumbents

• ResMed: ResMed is the global market leader in CPAP machines and related sleep-disordered breathing devices. It represents the incumbent standard-of-care that Mosanna's MOS118 is positioning against and a likely strategic acquirer or partner if MOS118 validates.
• Philips Respironics: Philips Respironics is a major manufacturer of CPAP devices and sleep diagnostics, and a long-standing OSA incumbent. Dr. David White, Mosanna's consulting CMO, previously served as its CMO, illustrating direct domain overlap.

Emerging players

• Incannex Healthcare: Incannex Healthcare is developing IHL-42X, a fixed-dose oral pharmaceutical for obstructive sleep apnea. It is an emerging clinical-stage competitor in the OSA pharmacotherapy space where Mosanna also operates.
• Sommetrics: Sommetrics is developing the aerSleep system, an external cervical collar device that maintains airway patency during sleep as a non-CPAP alternative for OSA — an emerging niche competitor addressing the same CPAP-intolerant population.
• Aerovate Therapeutics: Aerovate Therapeutics is developing an inhaled dry-powder formulation for pulmonary arterial hypertension. It is comparable as a clinical-stage biotech developing inhaled/nasal pulmonary therapeutics with similar CMC and formulation risk, though in a different therapeutic indication.
• Avadel Pharmaceuticals: Avadel Pharmaceuticals developed and now commercializes FT218 (LUMRYZ), a once-nightly sodium oxybate for narcolepsy. It is a comparable emerging specialty pharma with a once-nightly dosing CNS drug targeting a sleep-related disorder, sharing regulatory and commercial pathway characteristics with MOS118.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mosanna-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mosanna Therapeutics